ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Geoffrey Ku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.